Association between dopamine receptor genes and migraine without aura in a Sardinian sample

Neurology

Volumn 51, Issue 3, 1998, Pages 781-786

  Del Zompo, Maria ^a   Cherchi, A ^b   Palmas, M A ^b   Ponti, M ^b   Bocchetta, A ^b   Gessa, G L ^b   Piccardi, M P ^b  

^a Headache Center   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR;

ADOLESCENT; ADULT; ALLELISM; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINERGIC TRANSMISSION; FEMALE; GENE ISOLATION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR GENE;

EID: 0031782998     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.3.781     Document Type: Article

References (45)

1. Stewart WF, Lipton RB. Migraine headache: epidemiology and health care utilization. Cephalalgia 1993;36:383-388.
2. Russel MB, Rasmussen BK, Thornvaldesen P, Olesen J. Prevalence and sex ratio of the subtypes of migraine. Int J Epidemiol 1995;24:612-618.
3. Welch KMA, Barkley GL, Tepley N, Ramadan NM. Central neurogenic mechanisms of migraine. Neurology 1993;43(suppl 3):S21-S25.
4. Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 1993;13:151-165.
5. Sicuteri F. Dopamine, the second putative protagonist in headache. Headache 1977;17:129-131.
6. Peroutka SJ. Dopamine and migraine. Neurology 1997;49: 1-6.
7. Sorensen SA, Araki S. Genetics. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The headaches. New York: Raven Press, 1993:21-27.
8. Vilatela MEA, Pedroza FG, Ziegler DK, Mendez AG. Familial migraine in a Mexican population. Neuroepidemiology 1992; 11:46-49.
9. Russell MB, Olesen J. Increased familial risk and evidence of genetic factor in migraine. Br Med J 1995;311:541-544.
10. Joutel A, Bousser MG, Biousse V, et al. A gene for familial hemiplegic migraine maps to chromosome 19. Nat Genet 1993;5:40-45.
11. Ophoff RA, Terwindt GM, Vergouwe NIN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNLIA4. Cell 1996; 87:543-552.
12. Diriong S, Lory P, Williams ME, Ellis SB, Harpold MM, Taviaux S. Chromosomal localization of the human genes for alpha-1A, alpha-1B and alpha-IE voltage-dependent Ca(2+) channel subunits. Genomics 1995;30:605-609.
13. Hovatta I, Kallela M, Farkkila M, Peltonen L. Familial migraine: exclusion of the susceptibility gene from the reported locus of familial hemiplegic migraine on 19p. Genomics 1994; 23:707-709.
14. May A, Ophoff RA, Terwindt GM, et al. Familial hemiplegic migraine locus on 19p13 is involved in the common forms of migraine with and without aura. Hum Genet 1995;96:604-608.
15. Propping P, Nothen MM. Genetic variation of CNS receptors - a new perspective for pharmacogenetics. Pharmacogenetics 1995;5:318-325.
16. Peroutka SJ, Wilholt T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Ncol alleles. Neurology 1997;49:201-206.
17. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993; 52:506-516.
18. Spielman RS, Ewens WJ. The TDT and other family based tests for linkage disequilibrium and association. Am J Hum Genet 1996;59:983-989.
19. Cavalli-Sforza LL, Piazza A. Human genomic diversity, in Europe: a summary of recent research and prospects for the future. Eur J Hum Genet 1993;1:3-18.
20. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
21. Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991;19:44-54.
22. Hauge XY, Grandy DK, Eubanks JH, Evans GA, Civelli O, Litt M. Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics 1991;10:527-530.
23. Lannfelt L, Sokoloff P, Martres MP, et al. Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 1992; 2:249-256.
24. Van Tol HHM, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614.
25. Lichter JB, Barr CL, Kennedy JM, Van Tol HHM, Kidd KK, Livak KJ A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 1993;2:767-773.
26. Terwilliger JD. A powerful likelihood method for analysis of linkage disequilibrium between trait loci and one or more polymorphic marker loci. Am J Hum Genet 1995;56:777-787.
27. Ewens WS, Spielman RS. The transmission disequilibrium test: history, subdivision and admixture. Am J Hum Genet 1995;57:455-464.
28. Serra G, Collu M, Gessa GL. Yawning is elicited by D2 dopamine agonists but is blocked by the D1 antagonist, SCH 23390. Psychopharmacology 1987;91:330-333.
29. Ison PJ, Peroutka SJ. Neurotransmitter receptor binding predicts antiemetic efficacy and side effects. Cancer Treat Rep 1986;70:637-641.
30. Melis MR, Argiolas A, Gessa GL. Apomorphine-induced penile erection and yawning: site of action in brain. Brain Res 1987; 415:98-104.
31. Bès A, Dupui P, Guell A, et al. Dopamine and migraine. In: McKenzie E, Seylaz J, Bès A, eds. Neurotransmitters and the cerebral circulation, L.E.R.S. vol. 2. New York: Raven Press, 1984:157-173.
32. Sabatini U, Rascol O, Rascol A, Montastruc JL. Migraine attacks induced by subcutaneous apomorphine in two migrainous parkinsonian patients. Clin Neuropharmacol 1990;13: 264-267.
33. Fanciullacci M, Michelacci S, Curradi C, Sicuteri F. Hyperresponsiveness of migraine patients to the hypotensive action of bromocriptine. Headache 1980;20:99-102.
34. Geraud G, Bès A, Courtade M, et al. Interest of piribedil test to the diagnosis of migraine: result in 150 cases. Rev Neurol (Paris) 1983;139:215-218.
35. Del Zompo M, Lai M, Loi V, Pisano MR. Dopamine hypersensitivity in migraine: role in apomorphine syncope. Headache 1995;35:222-224.
36. Waelkens J. Domperidone in the prevention of complete classical migraine. Br Med J 1982;284:944. Letter.
37. Yealy DM. Acute pain management. Acad Emerg Med 1994;1: 186-189.
38. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med 1995;26:541-546.
39. McCulloch J, Harper AM. Cerebral circulation: effect of stimulation and blockade of dopamine receptors. Am J Physiol 1977;233:222-227.
40. Piccini P, Pavese N, Palombo C, Pittella G, Distante A, Bonuccelli U. Transcranial Doppler ultrasound in migraine and tension-type headache after apomorphine administration: double-blind crossover versus placebo study. Cephalalgia 1995;15:399-403.
41. Ambrosio C, Stefanini E. Interaction of flunarizine with dopamine D2 and D1 receptors. Eur J Pharmacol 1991;197:221-223.
42. Piccini P, Nuti A, Paoletti AM, Napolitano A, Melis GB, Bonuccelli U. Possible involvement of dopaminergic mechanisms in the antimigraine action of flunarizine. Cephalalgia 1990;10: 3-8.
43. Lugaresi A, Montagna P, Gallasi R, Lugaresi E. Extrapyramidal syndrome and depression induced by flunarizine. Eur Neurol 1988;28:208-211.
44. Barbanti P, Bronzetti E, Ricci A, et al. Increased density of dopamine D5 receptor in peripheral blood lymphocytes of migraineurs: a marker for migraine? Neurosci Lett 1996;207:73-76.
45. Del Zompo M, Lai M, Loi V, Pisano MR, Gessa GL. Apomorphine in migraineurs resistant to the prophylactic treatment. J Neural Transm 1996;103:10. Abstract.